Recap: Collegium Pharmaceutical Q4 Earnings
Portfolio Pulse from Benzinga Insights
Collegium Pharmaceutical (NASDAQ:COLL) reported Q4 earnings with an EPS of $1.58, surpassing the estimate of $0.66 by 139.39%. Revenue increased by $20.12 million from the same period last year. The company has consistently beaten EPS estimates over the past four quarters, leading to a 6.6% share price increase the day after last quarter's earnings were announced.
February 22, 2024 | 9:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Collegium Pharmaceutical reported a significant beat on Q4 earnings with an EPS of $1.58 against an estimate of $0.66 and a revenue increase of $20.12 million year-over-year.
The substantial beat on both EPS and revenue expectations, combined with the historical context of share price increase following earnings beats, suggests a positive short-term impact on COLL's stock price. The company's consistent performance in surpassing earnings estimates over the past year further strengthens investor confidence, likely leading to an uptick in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100